Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 inhibitors have been FDA approved: palbociclib, ribociclib and abemaciclib. Despite promising clinical outcomes, intrinsic or acq...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Cancer
Autori principali: Pandey, Kamal, An, Hee‐Jung, Kim, Seung Ki, Lee, Seung Ah, Kim, Sewha, Lim, Sun Min, Kim, Gun Min, Sohn, Joohyuk, Moon, Yong Wha
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2019
Soggetti:
Mini Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767051/
https://ncbi.nlm.nih.gov/pubmed/30478914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32020
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi